Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | MAP3K7 | O43318 | 5/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.34 |
| ▸ | MERTK | Q12866 | 3/20 | 0.34 |
| ▸ | INSR | P06213 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495365 | 0.93 | SYK (0.39) | SYKGABRG2GABRB3GABRA5CDK19 | |
| SCHEMBL3494877 | 0.91 | SYK (0.43) | SYKCDK19ALKMAP3K7IRAK4 | |
| SCHEMBL3496746 | 0.90 | SYK (0.38) | SYKCDK19ALKMAP3K7IRAK4 | |
| SCHEMBL3493833 | 0.84 | SYK (0.43) | SYKCDK19ALKMAP3K7IRAK4 | |
| SCHEMBL3497069 | 0.83 | SYK (0.38) | SYKCDK19ALKMAP3K7IRAK4 | |
| SCHEMBL3495108 | 0.83 | IRAK4 (0.37) | SYKCDK19ALKMAP3K7IRAK4 | |
| SCHEMBL3494271 | 0.81 | CYP1A2 (0.42) | SYKGABRG2GABRB3GABRA5MAP3K7 | |
| SCHEMBL3497184 | 0.81 | SYK (0.45) | SYKJAK2JAK1JAK3 | |
| SCHEMBL3496133 | 0.80 | CYP1A2 (0.42) | SYKMAP3K7IRAK4TYRO3MERTK | |
| SCHEMBL3495507 | 0.78 | CYP1A2 (0.43) | SYKMAP3K7IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | SYK 460/4885GABRG2 3763/4885GABRB3 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.